SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is actively trending due to breaking news of a Department of Justice criminal probe into Fed Chair Jerome Powell, which the community widely perceives as unprecedented political pressure on the central bank. This development is sparking intense debate among investors about the Federal Reserve's independence and its potential impact on future monetary policy, raising concerns about market stability and the dollar's credibility.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following its CES 2026 showcase, where it unveiled significant advancements in agentic voice and visual AI, including new partnerships with TomTom for multi-agent navigation and Richtech Robotics for automated food systems. The community is actively discussing these innovative applications in automotive and robotics, fueled by ongoing speculation about a potential short squeeze due to the stock's high short interest. Investors are keenly watching SOUN's position in the expanding AI market, highlighting its unique white-label solutions as a competitive advantage.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is drawing significant attention following its preliminary quarterly and full-year results, which reportedly surprised the market with strong revenue and improved adjusted EBITDA. The community is actively debating whether these positive developments, coupled with substantial insider buying and a notably low share float, signal a potential short squeeze or if lingering concerns about the company's cash position and dilution risks will temper sustained upside.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is currently trending due to heightened competitive pressures in the weight-loss market, specifically Amazon Pharmacy's offering of Novo Nordisk's oral GLP-1 at competitive prices, a product HIMS currently lacks. This news, compounded by a recent analyst downgrade, has driven significant bearish sentiment and a notable price correction. However, a segment of the community views the dip as an oversold opportunity, emphasizing HIMS' long-term strategy in personalized healthcare, proprietary compounding labs, and international expansion beyond just weight-loss treatments.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant upward momentum after announcing a record total contract value exceeding $1.1 billion for 2025, fueled by data agreements with over 70 pharmaceutical and biotech companies. This major business development highlights the strength of its AI-driven precision medicine platform, sparking widespread community excitement and further institutional interest in its role in advancing drug discovery and development.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as news circulates about a federal investigation into the Federal Reserve Chair, which is widely seen by the community as political pressure potentially undermining the central bank's independence. This has ignited debate among investors regarding its potential market impact on tech and growth stocks, though a "buy the dip" mentality is also evident.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a top trending stock as its highly anticipated earnings report approaches, with investors keenly awaiting commentary from Jamie Dimon regarding both strong profits and the economic outlook. The recent proposal to cap credit card interest rates is fueling significant debate on bank profitability, while JPM's warning on higher 2026 expenses has caused a notable dip. This dip is viewed by some as a buying opportunity, contrasting with concerns over rising costs and community discussions around potential silver short positions.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending amidst intense takeover speculation, notably involving Eli Lilly, following compelling Phase 3 data for its ulcerative colitis drug, obefazimod. The community is buzzing with discussions about potential significant acquisition offers and the drug's blockbuster market potential, positioning ABVX as a highly sought-after biotech asset. This M&A interest is further amplified by strong analyst confidence in obefazimod's differentiated profile within the competitive inflammatory bowel disease sector.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is experiencing extreme volatility following news of a new manufacturing partnership and a $10 million private placement, sparking intense debate between its operational progress and immediate dilution concerns. Community discussion centers on the potential for a massive short squeeze, with many comparing it to previous low-float runners, while others caution about dilution from the recent offering and the stock's significant price fluctuations.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as the community anticipates potential strategic updates from management at an upcoming healthcare conference, intensifying discussions around its perceived undervaluation and calls for new partnerships or a buyout. Investors are keenly focused on the company's protein-based vaccine platform and advanced adjuvant technology, while high short interest adds to the debate over its near-term trajectory amidst a dynamic biotech market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why You Should Add NI Stock to Your Portfolio Right Now

NiSource upgrades its grid, transitioning away from coal and maintaining shareholder payouts while investing up to $28.4B through 2030.

Here's Why You Should Add FTS Stock to Your Portfolio Right Now

FTS benefits from transmission expansion, grid modernization and rising data center demand, with steady earnings growth and a 3.54% dividend yield.

All You Need to Know About Edison International (EIX) Rating Upgrade to Strong Buy

Edison International (EIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Here's Why Edison International (EIX) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ED Benefits From Long-Term Capital Spending and Renewable Growth

Consolidated Edison is boosting grid reliability with major infrastructure investments, but regulatory rate risks could limit cost recovery.

Edison International $EIX Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its stake in Edison International (NYSE:EIX - Free Report) by 541.9% during the third quarter, according to its most recent 13F filing with the...

Edison International (NYSE:EIX) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Edison International from a "buy" rating to a "hold" rating in a research note on Wednesday...

Traders Purchase Large Volume of Edison International Call Options (NYSE:EIX)

Edison International (NYSE:EIX - Get Free Report) saw some unusual options trading on Tuesday. Traders acquired 94,754 call options on the stock. This represents an increase of 3,116% compared to the...

AES Stock Rises 28.6% in 6 Months: What Should Investors Do? 

AES shares are up 28.6% in six months as renewables, data center PPAs and LNG projects drive growth, but high debt tempers upside.

Here's Why You Should Include PEG Stock in Your Portfolio Now

Public Service Enterprise strengthens its appeal in the utility space with a solid ROE and steady dividend payments that continue to enhance shareholder value.

Edison International is a renewable energy company, which through its subsidiaries, generates and distributes electric power, and invests in energy services and technologies. The company was founded on July 4, 1886, and is headquartered in Rosemead, CA.

Edison International

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

EIX
Edison International

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest EIX News

EIXEdison International